What is EGRIFTA SV™ ?

When it's Hard Belly (excess hard abdominal fat)*,
it may be time for EGRIFTA SV

Treating Hard Belly (excess hard abdominal fat)
and maintaining your results
real patient

EGRIFTA SV™ is a newly FDA approved treatment* for Hard Belly (excess hard abdominal fat) in adult patients living with HIV and lipodystrophy.

EGRIFTA SV™ is not indicated for weight loss management; the impact and safety on cardiovascular health have not been studied; and it is not known whether taking EGRIFTA SV™ helps improve compliance with anti-retroviral medications.

EGRIFTA SV™ is a daily treatment that you inject subcutaneously (under the skin) around your lower abdomen (belly).

*A newly approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.

How EGRIFTA SV™ works

In some people living with HIV, Hard Belly (excess hard abdominal fat) occurs partly due to a reduced amount of growth hormone, which regulates how fat is stored in your body. Hard Belly fat is a different kind of fat; it lies deeper in the abdomen area, it is harder and firmer than the softer, squishy, regular fat that is just under the skin. Hard Belly fat can be difficult to control with just diet and exercise. In people living with HIV, EGRIFTA SV™ stimulates the production of growth hormone that helps to reduce the amount of Hard Belly fat.

Helping to reduce Hard Belly (excess hard abdominal fat) and maintain your results

Tesamorelin for injection (1 mg/vial) was studied in two clinical trials in adult patients living with HIV who developed Hard Belly (excess hard abdominal fat).
  • Each trial lasted 6 months, with an additional 6-month extension phase.
  • Patients receiving tesamorelin for injection saw significant reduction in Hard Belly (excess hard abdominal fat).

Reduction of Hard Belly (excess hard abdominal fat) was maintained for 1 year with

ongoing treatment (daily injections of tesamorelin).

Hard Belly (excess hard abdominal fat) returned when treatment with tesamorelin for injection was stopped.
For patients living with HIV, Hard Belly (excess hard abdominal fat) is a chronic condition. Even with taking EGRIFTA SV™ every day, it might take time to see results and maintain the reduction in Hard Belly (excess hard abdominal fat).
Talk to your healthcare provider about your treatment plan, the results you expect to see and feel, and any questions you may have while you are taking EGRIFTA SV™.
Reduction of Hard Belly (excess hard abdominal fat) maintained

People who used EGRIFTA SV™continually for one year saw significant reductions in Hard Belly (excess hard abdominal fat) over this time period.

Hard Belly (excess hard abdominal fat) returned when treatment was stopped

Hard Belly (excess hard abdominal fat) returned when EGRIFTA SV™ was stopped after 6 months of therapy.

EGRIFTA SV™ is not approved to reduce the health consequences of Hard Belly (excess hard abdominal fat).
EGRIFTA SV™ is not indicated for weight loss management.